Compare VanEck Australian Floating Rate ETF (FLOT) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93 (market cap $11.37B), while Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B). The key difference: VanEck Australian Floating Rate ETF and Globus Medical Inc. Class A Common Stock are close in size by market cap, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 23 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FLOT | GMED | |
|---|---|---|
Market Cap | $11.37B | $10.25B |
Volume | 2,911,131 | 1,059,528 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $96.82 |
52-Week Low | $50.72 | $58.33 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.95 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF benefits from floating rate exposure amid Fed tightening, with recent dividends of $0.17-$0.18 paid through October 2026. News highlights concentration risk with 47% bank exposure but positions FLOT as a cash substitute in rising rate environments.
Outlook remains tied to Fed policy, with floating rates offering yield advantage if hikes persist. Key risks include bank sector concentration and rate reversal. Analyst sentiment is cautious due to technical weakness but acknowledges strategic utility for barbell portfolios alongside duration assets.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
